Increased Expression of Fas Ligand mRNA and Protein in Liver Metastases of Human Colonic Adenocarcinomas

  • Hiroshi Takahashi
Conference paper


The Fas ligand (FasL) and its receptor (Fas, CD95) are a set of regulatory components in the immune system [1–4]. Activation of the Fas by FasL results in apoptosis of many cell types [5, 6], and this process has been shown to play a critical role in the maintenance of immunological homeostasis and peripheral tolerance by deletion of activated T-lymphocytes [7–10]. In addition, it has been found that cells in immunologically privileged sites, such as Sertoli’s cells of the testis and parenchymal cells of the anterior chamber of the eye, express FasL. Any activated T-cell bearing Fas that enters such a site would encounter cells expressing FasL and receive a death signal, thereby preventing an immune response [11,12].


Liver Metastasis Colon Cancer Cell SW480 Cell Colon Cancer Cell Line Human Colonic Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Itoh N, Yonehara S, Ishii A, et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243PubMedCrossRefGoogle Scholar
  2. 2.
    Suda T, Takahashi T, Golstein P, et al. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedCrossRefGoogle Scholar
  3. 3.
    Lynch DH, Ramsdell F, Alderson MR (1995) Fas and FasL in the home-ostatic regulation of immune responses. Immunol Today 16:569–574PubMedCrossRefGoogle Scholar
  4. 4.
    Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39–43PubMedCrossRefGoogle Scholar
  5. 5.
    Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456PubMedCrossRefGoogle Scholar
  6. 6.
    Cleveland JL, Ihle JN (1995) Contenders in FasL/TNF death signaling. Cell 81:479–482PubMedCrossRefGoogle Scholar
  7. 7.
    Singer GG, Abbas AK (1994) The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365–371PubMedCrossRefGoogle Scholar
  8. 8.
    Alderson MR, Tough TW, Davis-Smith T, et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71–77PubMedCrossRefGoogle Scholar
  9. 9.
    Brunner T, Mogil RJ, LaFace D, et al. (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441–444PubMedCrossRefGoogle Scholar
  10. 10.
    Dhein J, Walczak H, Baumler C, et al. (1995) Autocrine T-cell suicide mediated by APO-l/(Fas/CD95). Nature 373:438–441PubMedCrossRefGoogle Scholar
  11. 11.
    Bellgrau D, Gold D, Selawry H, et al. (1995) A role for CD95 ligand in preventing graft rejection. Nature 377:630–632PubMedCrossRefGoogle Scholar
  12. 12.
    Griffith TS, Brunner T, Fletcher SM, et al. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192PubMedCrossRefGoogle Scholar
  13. 13.
    Hahne M, Rimoldi D, Schroter M, et al. (1996) Melanoma cell expression of Fas (Apo-l/CD95) ligand: implications for tumor immune escape. Science 274:1363–1366PubMedCrossRefGoogle Scholar
  14. 14.
    Strand S, Hofmann WJ, Hug H, et al. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 2:1361–1366PubMedCrossRefGoogle Scholar
  15. 15.
    O’Connell J, O’Sullivan GC, Collins JK, et al. (1996) J Exp Med 184:1075–1082PubMedCrossRefGoogle Scholar
  16. 16.
    Morikawa K, Walker SM, Jessup JM, et al. (1988) In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48:1943–1948PubMedGoogle Scholar
  17. 17.
    Chelly J, Kaplan JC, Maire P, et al. (1988) Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature 333:858–860PubMedCrossRefGoogle Scholar
  18. 18.
    Nicoletti I, Migliorati G, Pagliacci MC, et al. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271–279PubMedCrossRefGoogle Scholar
  19. 19.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRefGoogle Scholar
  20. 20.
    Tanaka M, Suda T, Takahashi T, et al. (1995) Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 14:1129–1135PubMedGoogle Scholar
  21. 21.
    Tanaka M, Suda T, Haze K, et al. (1996) Fas ligand in human serum. Nat Med 2:317–322PubMedCrossRefGoogle Scholar
  22. 22.
    Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747–1756PubMedCrossRefGoogle Scholar
  23. 23.
    Weis M, Schlegel J, Kass GE, et al. (1995) Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. Exp Cell Res 219:699–708PubMedCrossRefGoogle Scholar
  24. 24.
    Nagata S (1997) Apoptosis by death factor. Cell 88:355–365PubMedCrossRefGoogle Scholar
  25. 25.
    Henkart PA (1994) Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343–346PubMedCrossRefGoogle Scholar
  26. 26.
    Berke G (1995) The CTL’s kiss of death. Cell 81:9–12PubMedCrossRefGoogle Scholar
  27. 27.
    Doherty PC (1993) Cell-mediated cytotoxicity. Cell 75:607–612PubMedCrossRefGoogle Scholar
  28. 28.
    Abbas AK (1996) Die and let live: eliminating dangerous lymphocytes. Cell 84:655–657PubMedCrossRefGoogle Scholar
  29. 29.
    Kubota Y, Sunouchi K, Ono M, et al. (1992) Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 35:645–650PubMedCrossRefGoogle Scholar
  30. 30.
    Underwood JC (1974) Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30:538–548PubMedCrossRefGoogle Scholar
  31. 31.
    Vose BM, Moore M (1985) Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 22:27–40PubMedGoogle Scholar
  32. 32.
    Seino K, Kayagaki N, Okumura K, et al. (1997) Antitumor effect of locally produced CD95 ligand. Nat Med 3:165–170PubMedCrossRefGoogle Scholar
  33. 33.
    Weiss L, Grundmann E, Torhorst J, et al. (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195–203PubMedCrossRefGoogle Scholar
  34. 34.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedCrossRefGoogle Scholar
  35. 35.
    Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:6130–6138PubMedGoogle Scholar
  36. 36.
    Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336PubMedCrossRefGoogle Scholar
  37. 37.
    Kuo TH, Kubota T, Watanabe, et al. (1995) Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci USA 92:12085–12089PubMedCrossRefGoogle Scholar
  38. 38.
    Spremuli EN, Dexter DL (1983) Human tumor cell heterogeneity and metastasis. J Clin Oncol 8:496–509Google Scholar
  39. 39.
    Fidler IJ (1989) Origin and biology of cancer metastasis. Cytometry 10:673–680PubMedCrossRefGoogle Scholar
  40. 40.
    Nigam AK, Pignateli M, Boulos PB (1994) Current concepts in metastasis. Gut 35:996–1000PubMedCrossRefGoogle Scholar
  41. 41.
    Galle PR, Hofmann WJ, Walczak H, et al. (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223–1230PubMedCrossRefGoogle Scholar
  42. 42.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364:806–809PubMedCrossRefGoogle Scholar
  43. 43.
    Ni R, Tomita Y, Matsuda K, et al. (1994) Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 215:332–337PubMedCrossRefGoogle Scholar
  44. 44.
    Owen-Schaub LB, Radinsky R, Kruzel E, et al. (1994) Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54:1580–1586PubMedGoogle Scholar
  45. 45.
    Shiraki K, Tsuji N, Shioda T, et al. (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94:6420–6425PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Hiroshi Takahashi
    • 1
  1. 1.Gastrointestinal Unit and Department of MedicineHarvard Medical School and Massachusetts General HospitalBostonUSA

Personalised recommendations